$RZLT News

Rezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026

Lake Street Maintains Buy on Rezolute, Raises Price Target to $12

Citizens Maintains Market Outperform on Rezolute, Raises Price Target to $15

Cantor Fitzgerald Upgrades Rezolute to Overweight

Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’

Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment

FDA Recommends Meeting for Rezolute Drug for Rare Blood Sugar Disorder Despite Missed Endpoints

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Rezolute Gets FDA Recommendation For Pre-BLA Meeting Ahead Of Ersodetug BLA Submission For Congenital Hyperinsulinism Treatment.

Lake Street Initiates Coverage On Rezolute with Buy Rating, Announces Price Target of $9

Craig-Hallum Upgrades Rezolute to Buy, Raises Price Target to $7

HC Wainwright & Co. Maintains Buy on Rezolute, Raises Price Target to $10

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

Rezolute Q4 EPS $(0.20) Misses $(0.15) Estimate

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Said FDA Is Still Reviewing Ersodetug Submission In Congenital Hyperinsulinism; The Company Continues To Await Feedback And Reserves The Ability To Request Formal Meeting Under Regulatory Timeline

Rezolute to Participate in Upcoming Investor Conferences

Rezolute to Participate in the BTIG Virtual Biotechnology Conference